{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:45:34Z","timestamp":1791963934392,"version":"4.3.4"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA282483"],"award-info":[{"award-number":["R01CA282483"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA233490"],"award-info":[{"award-number":["R01CA233490"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA187415"],"award-info":[{"award-number":["R01CA187415"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA138688"],"award-info":[{"award-number":["R01CA138688"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["RC1CA146299"],"award-info":[{"award-number":["RC1CA146299"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA214274-01A1"],"award-info":[{"award-number":["P01CA214274-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA214274-01A1"],"award-info":[{"award-number":["CA214274-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA233490"],"award-info":[{"award-number":["R01CA233490"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA187415"],"award-info":[{"award-number":["R01CA187415"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA138688"],"award-info":[{"award-number":["R01CA138688"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["RC1CA146299"],"award-info":[{"award-number":["RC1CA146299"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5KL2TR2734"],"award-info":[{"award-number":["5KL2TR2734"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pelotonia young investigator award"},{"name":"Pelotonia Graduate Fellowship."},{"name":"Pelotonia postdoctoral Fellowship."},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"Scholarship for the Next Generation of Scientists, Cancer Research Society."},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["(BT\/RLF\/Re-entry\/18\/2017"],"award-info":[{"award-number":["(BT\/RLF\/Re-entry\/18\/2017"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Society of Hematology Global Research Award"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"Canadian Institutes for Health Research, operating grant. Canadian Institutes for Health Research, New Investigator Award. Michael Smith Foundation for Health Research Scholar."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL) is a lethal hematological malignancy with a median survival of 4 years. Its lethality is mainly attributed to a limited understanding of clinical tumor progression and resistance to current therapeutic regimes. Intrinsic, prolonged drug treatment and tumor-microenvironment (TME) facilitated factors impart pro-tumorigenic and drug-insensitivity properties to MCL cells. Hence, elucidating neoteric pharmacotherapeutic molecular targets involved in MCL progression utilizing a global \u201cunified\u201d analysis for improved disease prevention is an earnest need. Using integrated transcriptomic analyses in MCL patients, we identified a Fibroblast Growth Factor Receptor-1 (FGFR1), and analyses of MCL patient samples showed that high FGFR1 expression was associated with shorter overall survival in MCL patient cohorts. Functional studies using pharmacological intervention and loss of function identify a novel MYC-EZH2-CDKN1C axis-driven proliferation in MCL. Further, pharmacological targeting with erdafitinib, a selective small molecule targeting FGFRs, induced cell-cycle arrest and cell death in-vitro, inhibited tumor progression, and improved overall survival in-vivo. We performed extensive pre-clinical assessments in multiple in-vivo model systems to confirm the therapeutic potential of erdafitinib in MCL and demonstrated FGFR1 as a viable therapeutic target in MCL.<\/jats:p>","DOI":"10.1038\/s41375-023-02006-8","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T13:01:42Z","timestamp":1692450102000},"page":"2094-2106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma"],"prefix":"10.1038","volume":"37","author":[{"given":"Anuvrat","family":"Sircar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-9566","authenticated-orcid":false,"given":"Satishkumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun Y.","family":"Xu-Monette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1309-4873","authenticated-orcid":false,"given":"Krysta Mila","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-6586","authenticated-orcid":false,"given":"Laura K.","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Chavdoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvathi","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8982-6877","authenticated-orcid":false,"given":"Walter","family":"Hanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Tsichlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-3579","authenticated-orcid":false,"given":"Blake R.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7632-1594","authenticated-orcid":false,"given":"Jianguo","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-4504","authenticated-orcid":false,"given":"Natarajan","family":"Muthusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5755-8932","authenticated-orcid":false,"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-7800","authenticated-orcid":false,"given":"Ryan","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-5427","authenticated-orcid":false,"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"key":"2006_CR1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma.","year":"1997","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood. 1997;89:3909\u201318.","journal-title":"Blood"},{"key":"2006_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.23615","volume":"88","author":"JM Vose","year":"2013","unstructured":"Vose JM. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2013;88:1082\u20138.","journal-title":"Am J Hematol"},{"key":"2006_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14:517\u201334.","journal-title":"Nat Rev Cancer"},{"key":"2006_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","volume":"131","author":"M Tiemann","year":"2005","unstructured":"Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131:29\u201338.","journal-title":"Br J Haematol"},{"key":"2006_CR5","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","volume":"124","author":"A Abrahamsson","year":"2014","unstructured":"Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D\u2019Amore F, et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood. 2014;124:1288\u201395.","journal-title":"Blood"},{"key":"2006_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cncr.23608","volume":"113","author":"Y Zhou","year":"2008","unstructured":"Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113:791\u20138.","journal-title":"Cancer"},{"key":"2006_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5","volume":"9","author":"A Kumar","year":"2019","unstructured":"Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9:50.","journal-title":"Blood Cancer J"},{"key":"2006_CR8","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559\u201363.","journal-title":"Blood"},{"key":"2006_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","volume":"26","author":"CY Cheah","year":"2015","unstructured":"Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26:1175\u20139.","journal-title":"Ann Oncol"},{"key":"2006_CR10","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256\u201369.","journal-title":"J Clin Oncol"},{"key":"2006_CR11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hon.2380","volume":"35","author":"N Epperla","year":"2017","unstructured":"Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \u201creal world\u201d study. Hematol Oncol. 2017;35:528\u201335.","journal-title":"Hematol Oncol"},{"key":"2006_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms21030904","volume":"21","author":"A Sircar","year":"2020","unstructured":"Sircar A, Chowdhury SM, Hart A, Bell WC, Singh S, Sehgal L, et al. Impact and intricacies of bone marrow microenvironment in B-cell lymphomas: from biology to therapy. Int J Mol Sci. 2020;21:904.","journal-title":"Int J Mol Sci"},{"key":"2006_CR13","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.4161\/cc.24928","volume":"12","author":"D Chiron","year":"2013","unstructured":"Chiron D, Martin P, Di Liberto M, Huang X, Ely S, Lannutti BJ, et al. Induction of prolonged early G1 arrest by CDK4\/CDK6 inhibition reprograms lymphoma cells for durable PI3K\u03b4 inhibition through PIK3IP1. Cell Cycle. 2013;12:1892\u20131900.","journal-title":"Cell Cycle"},{"key":"2006_CR14","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O Determann","year":"2008","unstructured":"Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385\u20137.","journal-title":"Blood"},{"key":"2006_CR15","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1002\/j.1460-2075.1994.tb06488.x","volume":"13","author":"SE Bodrug","year":"1994","unstructured":"Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13:2124\u201330.","journal-title":"EMBO J"},{"key":"2006_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-143038","volume":"136","author":"DR Edwards","year":"2020","unstructured":"Edwards DR, Kuo P-Y, Lagana A, Park S, Nedumaran P, Leshchenko V, et al. Aberrant cell cycle programming confers rapid lethality in the EuSOX11+ CCND1 MCL mouse model. Blood. 2020;136:6\u20137.","journal-title":"Blood"},{"key":"2006_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-019-1172-9","volume":"569","author":"DM Walter","year":"2019","unstructured":"Walter DM, Yates TJ, Ruiz-Torres M, Kim-Kiselak C, Gudiel AA, Deshpande C, et al. RB constrains lineage fidelity and multiple stages of tumour progression and metastasis. Nature. 2019;569:423\u20137.","journal-title":"Nature"},{"key":"2006_CR18","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov. 2020;10:1174\u201393.","journal-title":"Cancer Discov"},{"key":"2006_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","volume":"139","author":"R Roskoski Jr","year":"2019","unstructured":"Roskoski R Jr. Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs. Pharmacol Res. 2019;139:471\u201388.","journal-title":"Pharmacol Res"},{"key":"2006_CR20","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","volume":"133","author":"P Martin","year":"2019","unstructured":"Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133:1201\u20134.","journal-title":"Blood"},{"key":"2006_CR21","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.febslet.2006.01.095","volume":"580","author":"P Dvorak","year":"2006","unstructured":"Dvorak P, Dvorakova D, Hampl A. Fibroblast growth factor signaling in embryonic and cancer stem cells. FEBS Lett. 2006;580:2869\u201374.","journal-title":"FEBS Lett"},{"key":"2006_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.cytogfr.2005.01.003","volume":"16","author":"R Grose","year":"2005","unstructured":"Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 2005;16:179\u201386.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2006_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2174\/156800909789057006","volume":"9","author":"M Korc","year":"2009","unstructured":"Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Current Cancer Drug Targets. 2009;9:639\u201351.","journal-title":"Current Cancer Drug Targets"},{"key":"2006_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/152581602753448513","volume":"11","author":"E Moroni","year":"2002","unstructured":"Moroni E, Dell\u2019Era P, Rusnati M, Presta M. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res. 2002;11:19\u201332.","journal-title":"J Hematother Stem Cell Res"},{"key":"2006_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdisc Rev Dev Biol. 2015;4:215\u201366.","journal-title":"Wiley Interdisc Rev Dev Biol"},{"key":"2006_CR26","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/sj.bjc.6600330","volume":"86","author":"I Pazgal","year":"2002","unstructured":"Pazgal I, Zimra Y, Tzabar C, Okon E, Rabizadeh E, Shaklai M, et al. Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin\u2019s lymphoma. Br J Cancer. 2002;86:1770\u20135.","journal-title":"Br J Cancer"},{"key":"2006_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116\u201329.","journal-title":"Nat Rev Cancer"},{"key":"2006_CR28","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1158\/0008-5472.CAN-08-3398","volume":"69","author":"W Xian","year":"2009","unstructured":"Xian W, Pappas L, Pandya D, Selfors LM, Derksen PW, de Bruin M, et al. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res. 2009;69:2244\u201351.","journal-title":"Cancer Res"},{"key":"2006_CR29","doi-asserted-by":"publisher","first-page":"15694","DOI":"10.1074\/jbc.M601252200","volume":"281","author":"X Zhang","year":"2006","unstructured":"Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006;281:15694\u201315700.","journal-title":"J Biol Chem"},{"key":"2006_CR30","doi-asserted-by":"publisher","first-page":"55348","DOI":"10.1074\/jbc.M409230200","volume":"279","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Lin Y, Bowles C, Wang F. Direct cell cycle regulation by the fibroblast growth factor receptor (FGFR) kinase through phosphorylation-dependent release of Cks1 from FGFR substrate 2. J Biol Chem. 2004;279:55348\u201354.","journal-title":"J Biol Chem"},{"key":"2006_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer Research. 2016;22:259\u201367.","journal-title":"Clinical Cancer Research"},{"key":"2006_CR32","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood-2009-05-217182","volume":"116","author":"H Agerstam","year":"2010","unstructured":"Agerstam H, Jaras M, Andersson A, Johnels P, Hansen N, Lassen C, et al. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. Blood. 2010;116:2103\u201311.","journal-title":"Blood"},{"key":"2006_CR33","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3324\/haematol.2019.220871","volume":"105","author":"MN Peiris","year":"2020","unstructured":"Peiris MN, Meyer AN, Nelson KN, Bisom-Rapp EW, Donoghue DJ. Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. Haematologica. 2020;105:1262\u201373.","journal-title":"Haematologica"},{"key":"2006_CR34","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1016\/j.leukres.2011.05.013","volume":"35","author":"JJ Wakim","year":"2011","unstructured":"Wakim JJ, Tirado CA, Chen W, Collins R. t(8;22)\/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. Leuk Res. 2011;35:e151\u2013153.","journal-title":"Leuk Res"},{"key":"2006_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, et al. Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nature Communications. 2019;10:1373.","journal-title":"Nature Communications"},{"key":"2006_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.","journal-title":"Nat Commun"},{"key":"2006_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","volume":"3","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185\u201397.","journal-title":"Cancer Cell"},{"key":"2006_CR38","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1182\/blood.2019002385","volume":"136","author":"P Pararajalingam","year":"2020","unstructured":"Pararajalingam P, Coyle KM, Arthur SE, Thomas N, Alcaide M, Meissner B, et al. Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. Blood. 2020;136:572\u201384.","journal-title":"Blood"},{"key":"2006_CR39","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood.2020005289","volume":"136","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Martin-Garcia D, Clot G, D\u00edaz-Navarro A, Duran-Ferrer M, Navarro A, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020;136:1419\u201332.","journal-title":"Blood"},{"key":"2006_CR40","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","volume":"16","author":"TPS Perera","year":"2017","unstructured":"Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, et al. Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017;16:1010\u201320.","journal-title":"Mol Cancer Ther"},{"key":"2006_CR41","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A. Erdafitinib: First Global Approval. Drugs. 2019;79:1017\u201321.","journal-title":"Drugs"},{"key":"2006_CR42","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene set knowledge discovery with enrichr. Current Protocols. 2021;1:e90.","journal-title":"Current Protocols"},{"key":"2006_CR43","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","volume":"30","author":"AC Queiros","year":"2016","unstructured":"Queiros AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, et al. Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage. Cancer Cell. 2016;30:806\u201321.","journal-title":"Cancer Cell"},{"key":"2006_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03751-6","volume":"9","author":"A Lachmann","year":"2018","unstructured":"Lachmann A, Torre D, Keenan AB, Jagodnik KM, Lee HJ, Wang L, et al. Massive mining of publicly available RNA-seq data from human and mouse. Nature Communications. 2018;9:1366.","journal-title":"Nature Communications"},{"key":"2006_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1100-9","volume":"14","author":"X Wang","year":"2016","unstructured":"Wang X, Sehgal L, Jain N, Khashab T, Mathur R, Samaniego F. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2. J Transl Med. 2016;14:346.","journal-title":"J Transl Med"},{"key":"2006_CR46","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1101\/gad.9.6.650","volume":"9","author":"S Matsuoka","year":"1995","unstructured":"Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, et al. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995;9:650\u201362.","journal-title":"Genes Dev"},{"key":"2006_CR47","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","volume":"13","author":"CJ Sherr","year":"1999","unstructured":"Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501\u201312.","journal-title":"Genes Dev"},{"key":"2006_CR48","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1210\/mend.13.11.0379","volume":"13","author":"MKR Samuelsson","year":"1999","unstructured":"Samuelsson MKR, Pazirandeh A, Davani B, Okret S. p57Kip2, a Glucocorticoid-Induced Inhibitor of Cell Cycle Progression in HeLa Cells. Molecular Endocrinology. 1999;13:1811\u201322.","journal-title":"Molecular Endocrinology"},{"key":"2006_CR49","doi-asserted-by":"publisher","first-page":"9813","DOI":"10.1074\/jbc.M109.091496","volume":"285","author":"Y Ma","year":"2010","unstructured":"Ma Y, Chen L, Wright GM, Pillai SR, Chellappan SP, Cress WD. CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner. J Biol Chem. 2010;285:9813\u201322.","journal-title":"J Biol Chem"},{"key":"2006_CR50","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1128\/MCB.15.2.742","volume":"15","author":"XQ Qin","year":"1995","unstructured":"Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z, Kaelin WG Jr. The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol. 1995;15:742\u201355.","journal-title":"Mol Cell Biol"},{"key":"2006_CR51","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1073\/pnas.062047499","volume":"99","author":"J Wells","year":"2002","unstructured":"Wells J, Graveel CR, Bartley SM, Madore SJ, Farnham PJ. The identification of E2F1-specific target genes. Proc Nat Acad Sci. 2002;99:3890\u20135.","journal-title":"Proc Nat Acad Sci"},{"key":"2006_CR52","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1523\/JNEUROSCI.2840-13.2014","volume":"34","author":"L Magri","year":"2014","unstructured":"Magri L, Swiss VA, Jablonska B, Lei L, Pedre X, Walsh M, et al. E2F1 coregulates cell cycle genes and chromatin components during the transition of oligodendrocyte progenitors from proliferation to differentiation. J Neurosci. 2014;34:1481\u201393.","journal-title":"J Neurosci"},{"key":"2006_CR53","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.onc.1205102","volume":"21","author":"S Polager","year":"2002","unstructured":"Polager S, Kalma Y, Berkovich E, Ginsberg D. E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene. 2002;21:437\u201346.","journal-title":"Oncogene"},{"key":"2006_CR54","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.tibs.2004.06.006","volume":"29","author":"AP Bracken","year":"2004","unstructured":"Bracken AP, Ciro M, Cocito A, Helin K. E2F target genes: unraveling the biology. Trends Biochem Sci. 2004;29:409\u201317.","journal-title":"Trends Biochem Sci"},{"key":"2006_CR55","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1535-7163.MCT-15-0750","volume":"15","author":"X Wu","year":"2016","unstructured":"Wu X, Liu D, Tao D, Xiang W, Xiao X, Wang M, et al. BRD4 regulates EZH2 transcription through upregulation of C-MYC and represents a novel therapeutic target in bladder cancer. Mol Cancer Therap. 2016;15:1029\u201342.","journal-title":"Mol Cancer Therap"},{"key":"2006_CR56","doi-asserted-by":"publisher","first-page":"33061","DOI":"10.1074\/jbc.M111.257667","volume":"286","author":"A Tzatsos","year":"2011","unstructured":"Tzatsos A, Paskaleva P, Lymperi S, Contino G, Stoykova S, Chen Z, et al. Lysine-specific Demethylase 2B (KDM2B)-let-7-Enhancer of Zester Homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. J Biolog Chem. 2011;286:33061\u20139.","journal-title":"J Biolog Chem"},{"key":"2006_CR57","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1101\/gad.836800","volume":"14","author":"R Sears","year":"2000","unstructured":"Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501\u201314.","journal-title":"Genes Dev"},{"key":"2006_CR58","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.emboj.7600217","volume":"23","author":"M Yada","year":"2004","unstructured":"Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004;23:2116\u201325.","journal-title":"EMBO J"},{"key":"2006_CR59","doi-asserted-by":"publisher","first-page":"9085","DOI":"10.1073\/pnas.0402770101","volume":"101","author":"M Welcker","year":"2004","unstructured":"Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA. 2004;101:9085\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2006_CR60","doi-asserted-by":"publisher","first-page":"e1000013","DOI":"10.1371\/journal.pcbi.1000013","volume":"4","author":"T Lee","year":"2008","unstructured":"Lee T, Yao G, Nevins J, You L. Sensing and integration of Erk and PI3K signals by Myc. PLoS Comput Biol. 2008;4:e1000013.","journal-title":"PLoS Comput Biol"},{"key":"2006_CR61","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccr.2007.11.004","volume":"12","author":"VD Acevedo","year":"2007","unstructured":"Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12:559\u201371.","journal-title":"Cancer Cell"},{"key":"2006_CR62","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/bjc.2013.550","volume":"109","author":"PT Nguyen","year":"2013","unstructured":"Nguyen PT, Tsunematsu T, Yanagisawa S, Kudo Y, Miyauchi M, Kamata N, et al. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1. Br J Cancer. 2013;109:2248\u201358.","journal-title":"Br J Cancer"},{"key":"2006_CR63","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/cells10051154","volume":"10","author":"L Pacini","year":"2021","unstructured":"Pacini L, Jenks AD, Lima NC, Huang PH. Targeting the fibroblast growth factor receptor (FGFR) family in lung cancer. Cells. 2021;10:1154.","journal-title":"Cells"},{"key":"2006_CR64","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1182\/blood.V85.7.1881.bloodjournal8571881","volume":"85","author":"RC Inhorn","year":"1995","unstructured":"Inhorn RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R, et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia\/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995;85:1881\u20137.","journal-title":"Blood"},{"key":"2006_CR65","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/gcc.1177","volume":"32","author":"J Sohal","year":"2001","unstructured":"Sohal J, Chase A, Mould S, Corcoran M, Oscier D, Iqbal S, et al. Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer. 2001;32:155\u201363.","journal-title":"Genes Chromosomes Cancer"},{"key":"2006_CR66","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.3390\/cancers13122968","volume":"13","author":"A Kommalapati","year":"2021","unstructured":"Kommalapati A, Tella SH, Borad M, Javle M, Mahipal A. FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice. Cancers. 2021;13:2968.","journal-title":"Cancers"},{"key":"2006_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","volume":"38","author":"M Katoh","year":"2016","unstructured":"Katoh M. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med. 2016;38:3\u201315.","journal-title":"Int J Mol Med"},{"key":"2006_CR68","first-page":"181","volume":"5","author":"Y Xie","year":"2020","unstructured":"Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, et al. FGF\/FGFR signaling in health and disease. Signal Transd Targ Ther. 2020;5:181.","journal-title":"Signal Transd Targ Ther"},{"key":"2006_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2013.4","volume":"2","author":"KE Ware","year":"2013","unstructured":"Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013;2:e39.","journal-title":"Oncogenesis"},{"key":"2006_CR70","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1158\/0008-5472.CAN-15-3569","volume":"76","author":"E Traer","year":"2016","unstructured":"Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, et al. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Res. 2016;76:6471\u201382.","journal-title":"Cancer Res"},{"key":"2006_CR71","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1158\/2159-8290.CD-14-0763","volume":"5","author":"F Li","year":"2015","unstructured":"Li F, Huynh H, Li X, Ruddy DA, Wang Y, Ong R, et al. FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors. Cancer Discov. 2015;5:438\u201351.","journal-title":"Cancer Discov"},{"key":"2006_CR72","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/cells10051201","volume":"10","author":"HR Ferguson","year":"2021","unstructured":"Ferguson HR, Smith MP, Francavilla C. Fibroblast growth factor receptors (FGFRs) and noncanonical partners in cancer signaling. Cells. 2021;10:1201.","journal-title":"Cells"},{"key":"2006_CR73","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/sj.leu.2402861","volume":"17","author":"P Krejci","year":"2003","unstructured":"Krejci P, Faitova J, Laurell H, Hampl A, Dvorak P. FGF-2 expression and its action in human leukemia and lymphoma cell lines. Leukemia. 2003;17:818\u201320.","journal-title":"Leukemia"},{"key":"2006_CR74","doi-asserted-by":"publisher","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","volume":"11","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019;11:eaau1167.","journal-title":"Sci Transl Med"},{"key":"2006_CR75","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Iannotti NO, Gutierrez M, Smith DC, F\u00e9liz L, Lihou CF, et al. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies. Ann Oncol. 2022;33:522\u201333.","journal-title":"Ann Oncol"},{"key":"2006_CR76","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nature02985","volume":"431","author":"H Wang","year":"2004","unstructured":"Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature. 2004;431:873\u20138.","journal-title":"Nature"},{"key":"2006_CR77","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.molcel.2012.01.002","volume":"45","author":"Z Gao","year":"2012","unstructured":"Gao Z, Zhang J, Bonasio R, Strino F, Sawai A, Parisi F, et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell. 2012;45:344\u201356.","journal-title":"Mol Cell"},{"key":"2006_CR78","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.molcel.2011.06.020","volume":"43","author":"F Kottakis","year":"2011","unstructured":"Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, Tsichlis PN. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1\/KDM2B-miR-101-EZH2 pathway. Mol Cell. 2011;43:285\u201398.","journal-title":"Mol Cell"},{"key":"2006_CR79","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1111\/cas.14905","volume":"112","author":"Y Kagiyama","year":"2021","unstructured":"Kagiyama Y, Fujita S, Shima Y, Yamagata K, Katsumoto T, Nakagawa M, et al. CDKN1C-mediated growth inhibition by an EZH1\/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib. Cancer Sci. 2021;112:2314\u201324.","journal-title":"Cancer Sci"},{"key":"2006_CR80","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","volume":"22","author":"AP Bracken","year":"2003","unstructured":"Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003;22:5323\u201335.","journal-title":"EMBO J"},{"key":"2006_CR81","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1076997","volume":"298","author":"R Cao","year":"2002","unstructured":"Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002;298:1039\u201343.","journal-title":"Science"},{"key":"2006_CR82","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1101\/gad.269603","volume":"17","author":"J Min","year":"2003","unstructured":"Min J, Zhang Y, Xu RM. Structural basis for specific binding of Polycomb chromodomain to histone H3 methylated at Lys 27. Genes Dev. 2003;17:1823\u20138.","journal-title":"Genes Dev"},{"key":"2006_CR83","doi-asserted-by":"publisher","first-page":"e00205","DOI":"10.7554\/eLife.00205","volume":"1","author":"AM Farcas","year":"2012","unstructured":"Farcas AM, Blackledge NP, Sudbery I, Long HK, McGouran JF, Rose NR, et al. KDM2B links the Polycomb Repressive Complex 1 (PRC1) to recognition of CpG islands. Elife. 2012;1:e00205.","journal-title":"Elife"},{"key":"2006_CR84","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s12185-019-02600-6","volume":"110","author":"G Sashida","year":"2019","unstructured":"Sashida G, Oshima M, Iwama A. Deregulated Polycomb functions in myeloproliferative neoplasms. Int J Hematol. 2019;110:170\u20138.","journal-title":"Int J Hematol"},{"key":"2006_CR85","doi-asserted-by":"publisher","first-page":"530","DOI":"10.20892\/j.issn.2095-3941.2018.0380","volume":"16","author":"W Li","year":"2019","unstructured":"Li W, Bi C, Han Y, Tian T, Wang X, Bao H, et al. Targeting EZH1\/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma. Cancer Biol Med. 2019;16:530\u201341.","journal-title":"Cancer Biol Med"},{"key":"2006_CR86","doi-asserted-by":"publisher","first-page":"108870","DOI":"10.1016\/j.celrep.2021.108870","volume":"34","author":"X Zhao","year":"2021","unstructured":"Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, et al. Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Rep. 2021;34:108870.","journal-title":"Cell Rep"},{"key":"2006_CR87","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/sj.leu.2401599","volume":"13","author":"L Hernandez","year":"1999","unstructured":"Hernandez L, Hernandez S, Bea S, Pinyol M, Ferrer A, Bosch F, et al. c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin\u2019s lymphomas. Leukemia. 1999;13:2087\u201393.","journal-title":"Leukemia"},{"key":"2006_CR88","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1038\/leu.2013.94","volume":"27","author":"X Zhao","year":"2013","unstructured":"Zhao X, Lwin T, Zhang X, Huang A, Wang J, Marquez VE, et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia. 2013;27:2341\u201350.","journal-title":"Leukemia"},{"key":"2006_CR89","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533\u20138.","journal-title":"Nature"},{"key":"2006_CR90","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1002\/j.1460-2075.1994.tb06655.x","volume":"13","author":"H Lovec","year":"1994","unstructured":"Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1\/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487\u201395.","journal-title":"EMBO J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02006-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02006-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02006-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:04:02Z","timestamp":1695920642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02006-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":90,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2006"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02006-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]},"assertion":[{"value":"10 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}